Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNITY trial of subcutaneous efgartigimod PH20 in primary Sjögren's disease
NL-OMON59056Phase 3Completed
- Sponsor
- argenx
- Start
- May 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Sjögren's syndrome comparing Efgartigimod PH20 SC with Placebo PH20 SC (2 arms). Primary endpoint: Change from baseline in clinESSDAI score at week 48. Started May 2025; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON59056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59056.